Brahms gets FDA approval for sepsis test:
This article was originally published in Clinica
German diagnostic company Brahms has received clearance to sell in the US its inflammatory response marker for sepsis, Procalcitonin (PCT). The Berlin-based company said PCT is designed to aid in the risk assessment of critically ill patients, on their first day of ICU admission, for progression to severe sepsis and septic shock. The product is already available in Europe.